Are you using real-world evidence?
Parexel’s experts offer a roadmap and best practices for current RWE applications across three development arenas:
- Early asset planning
- Clinical development: Meeting regulatory expectations
- Medical marketplace: Demonstrating value in the real world
In each section of this playbook, we highlight examples of recent Parexel projects that illustrate the power of RWE to improve decision-making and to drive cost- and times-saving development strategies.
Related Insights
Article
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
May 10, 2022
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Blog
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
May 16, 2022
Blog
Summary and assessment: Using Artificial Intelligence & Machine Learning in the Development of Drug & Biological Products: Discussion Paper and Request for Feedback (FDA)
Mar 7, 2024
Blog
Summary and assessment of EMA’s reflection paper on the use of artificial intelligence (AI) in the medicinal product lifecycle
Mar 7, 2024
Blog
Regulatory acceptability of AI: Current perspectives
Mar 7, 2024
Article
How biotechs can strengthen their value story with advanced analytics
Feb 15, 2022
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Blog
Using ethical AI to streamline HEOR
Jan 26, 2024
Blog
AI Milestones: FDA’s ISTAND program accepts AI-based assessment tool for depression
Mar 19, 2024
Article
Lessons from China and the United States on the use of RWE in regulatory submissions
Jul 19, 2021
Related Insights
Article
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
May 10, 2022
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Blog
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
May 16, 2022
Blog
Summary and assessment: Using Artificial Intelligence & Machine Learning in the Development of Drug & Biological Products: Discussion Paper and Request for Feedback (FDA)
Mar 7, 2024
Blog
Summary and assessment of EMA’s reflection paper on the use of artificial intelligence (AI) in the medicinal product lifecycle
Mar 7, 2024
Blog
Regulatory acceptability of AI: Current perspectives
Mar 7, 2024
Article
How biotechs can strengthen their value story with advanced analytics
Feb 15, 2022
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Blog
Accelerating Delivery and Patient Access to Rare Disease Treatments – Highlights from World Orphan Drug Congress
May 2, 2024
Blog
Using ethical AI to streamline HEOR
Jan 26, 2024
Blog
AI Milestones: FDA’s ISTAND program accepts AI-based assessment tool for depression
Mar 19, 2024
Article
Lessons from China and the United States on the use of RWE in regulatory submissions
Jul 19, 2021